Questionable Sales Practices in the Drug Industry: Hearing Before the Subcommittee on Regulation, Business Opportunities, and Technology of the Committee on Small Business, House of Representatives, One Hundred Third Congress, Second Session, Washington, DC, October 12, 1994, Volume 4Distributed to some depository libraries in microfiche. |
Other editions - View all
Common terms and phrases
abuses adult height agency antikickback approved Ayerst benefit Brown Business Opportunities cancer Caremark Chairman WYDEN Charlotte child clinical concern criminal discuss disease doctors drug companies drug promotion effects evaluation FDA's Federal Food and Drug funds Genentech growing growth disorders growth failure growth hormone deficiency growth hormone therapy growth hormone treatment growth screening health care fraud health screenings height screening Hoffmann-LaRoche Human Growth Foundation human growth hormone Humatrope indicated investigation involved issues kickbacks label letter Lilly MacGillivray Medicaid Medicare normal nurse off-label parents patients payment pediatric endocrinologist PENDERGAST pharmaceutical companies pharmaceutical industry physicians pituitary post-marketing potential practices prescribe prescription drug prescription drug marketing problems promotional activities promotional materials Protropin providers public health questions reimbursement risk ROGOL Ron Wyden scientific screening programs short stature sponsored Subcommittee on Regulation Technology tests Towle treated Turner Syndrome unapproved